Hutchmed (China) (HCM) said late Monday it completed enrollment in the registration phase of a phase II trial to assess the efficacy, safety and tolerability of savolitinib in gastric cancer patients with MET amplification.
A total of 64 patients have been enrolled in the trial.
If positive, the company may begin plans to apply for marketing authorization of savolitinib for gastric cancer in China later this year, it said.
Savolitinib is being jointly developed by AstraZeneca (AZN) and Hutchmed, and commercialized by AstraZeneca.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.